NCT00894322 - A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide once weekly

subcutaneous injection, 10.0 mg, single injection

DRUG

exenatide once weekly

subcutaneous injection, 2.0 mg, once a week for 12 weeks

OTHER

Placebo

subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks

Trial Locations (1)

Research Site, Lincoln